Who, What, Where

Steve Schauer and Steven Chwiecko have new jobs at First Wind, a wind power company headquartered in Newton. Schauer, who has served as First Wind's vice president of finance since joining the company in November 2008, was promoted to senior vice president of finance and treasurer. In this new position, he will be responsible for all project finance, tax equity, corporate debt capital, and treasury operations. Chwiecko joins the company as senior vice president of commercial asset management. Mr. Chwiecko has more than 25 years of experience in the unregulated power generation area focusing on asset management and acquisitions, most recently for Atlantic Power Corp. In this newly created role at First Wind, Chwiecko will oversee the company's leases, power sales agreements, REC sales contracts, and interconnection agreements for current operating wind projects.

Jonathan Lieber has been appointed as chief financial officer of Xcellerex Inc., a Marlborough company that specializes in how biomolecules are developed, manufactured, and commercialized into biotherapeutics and vaccines. Lieber joins Xcellerex from Altus Pharmaceuticals, where he was senior vice president, chief financial officer, and treasurer.

Michael Kaicher has been hired to the position of senior vice president of business development at Capital Advisors Group, an institutional investment advisor based in Newton. He will focus on mid- to large-cap corporations in New York and New Jersey. Prior to joining Capital Advisors Group, Kaicher served as senior vice president and sales director of Evergreen Investments' Short Duration Institutional Asset Management Group.

Amee Chande (right) is the new senior vice president of strategy at Staples Inc., the Framingham-based retailer of office supplies. In that job, she is responsible for working with senior management to develop all elements of the company's global strategy and reports to John Mahoney, the company's vice chairman and chief financial officer. Chande joins Staples from Wal-Mart Stores Inc., where she served most recently as vice president of new business development, Staples said.

David M. Madden has been appointed as the independent chairman of the board at Dicerna Pharmaceuticals Inc., a Watertown company that is looking to develop drugs through RNA interference. Madden has held leadership positions in the biopharmaceutical industry for over 15 years. Most recently, he served as interim chief executive for Adolor Corp., a publicly traded pharmaceutical company with a focus on pain management. Douglas M. Fambrough, general partner with Oxford Biosciences Partners and previous chairman, remains on the now six-person Dicerna board.